Delarue J C, Friedman S, Mouriesse H, May-Levin F, Sancho-Garnier H, Contesso G
Hormonal Biochemistry Laboratory, Institut Gustave-Roussy, Villejuif, France.
Breast Cancer Res Treat. 1988 May;11(2):173-8. doi: 10.1007/BF01805841.
Epidermal growth factor receptor (EGFR), determined by the Scatchard curve method, was found in 22 cases of a random series of 100 patients with breast carcinoma. Two groups of patients were identified, one (n = 16) with a low concentration (0-50 fm/mg protein) of EGFR but with a high affinity (Kd = 3.2 nM), and the other (n = 6) with a high concentration (90-210 fm/mg protein) of EGFR but with a lower affinity (Kd = 6.3 nM). A significant inverse relationship was found between the presence of EGFR and receptors for estrogen (p less than 0.001) and progesterone (p = 0.001). EGFR was found in no (0/8) tumors with Grade I histoprognostic grade, 17% (10/58) Grade II, and 38% (11/29) Grade III (p less than 0.05). EGFR is present therefore in poorly differentiated tumors and associated with other factors of poor prognosis. Our in vivo analyses confirm results found in tissue culture derived from human breast carcinoma cells.
采用Scatchard曲线法测定表皮生长因子受体（EGFR），在随机选取的100例乳腺癌患者中，有22例检测到该受体。确定了两组患者，一组（n = 16）EGFR浓度低（0 - 50 fm/mg蛋白质）但亲和力高（Kd = 3.2 nM），另一组（n = 6）EGFR浓度高（90 - 210 fm/mg蛋白质）但亲和力较低（Kd = 6.3 nM）。发现EGFR的存在与雌激素受体（p < 0.001）和孕激素受体（p = 0.001）之间存在显著的负相关。在组织学预后分级为I级的肿瘤中未发现EGFR（0/8），II级肿瘤中为17%（10/58），III级肿瘤中为38%（11/29）（p < 0.05）。因此，EGFR存在于低分化肿瘤中，并与其他预后不良因素相关。我们的体内分析证实了在源自人乳腺癌细胞的组织培养中发现的结果。
